COMPARE · Reviewed July 17, 2026
NBIX vs VEEV
Verdict: Side-by-side breakdown using the Bull Rankings model. NBIX scored 87.6, VEEV scored 82.4 — NBIX leads.
Compare another set
NBIX
Neurocrine Biosciences, Inc.
87.6
$170.88 · $17.2B
Score gap
5.2
NBIX leads
VEEV
Veeva Systems Inc.
82.4
$195.38 · $31.7B
The model, pillar by pillar (0–100 each)
NBIX
stronger →← stronger
VEEV
82
Qualityreturns · margins · balance sheet
77
100
Growthrevenue & earnings expansion
94
82
Valuevaluation vs sector peers
77
NBIX is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
NBIX
VEEV
$831mC+
FCF
$1.7bC+
+28.6%A-
Rev
+16.2%B+
0.14B+
D/E
0.01A-
26.3xB
P/E
34.6xC+
0.49A
PEG
0.87B+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
NBIX
VEEV
11% below
Price vs fair valuelower is cheaper
4% above
~11%/yr
Growth the price implies10-yr FCF · lower = less priced in
~8%/yr
-14%
1-yr DCF upside
-13%
+12%
5-yr DCF upside
-4%
+66%
10-yr DCF upside
+11%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
NBIX
Why this score
- Durable high returns
VEEV
No notable signals flagged.
The companies
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $17.2b. 6% off the 52-week high of $181.18. Revenue growing +29% — in hypergrowth territory. PEG 0.49 — paying under fair value for the growth rate. 28 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $199.27 (implying +17% upside).
Moat
Net margin 22% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 124% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
VEEVVeeva Systems Inc.
Why now
Health Information Services · market cap $31.7b. Down 37% from 52-week high of $310.50 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. PEG 0.87 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Buy with a mean 1-yr target of $244.59 (implying +25% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 37% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 35x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.